Responses
Regular and young investigator award abstracts
Clinical trials in progress
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
Compose a Response to This Article
Other responses
No responses have been published for this article.
